https://www.optimumcomms.com/wp-content/uploads/2026/10/rouge-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-06 08:38:382026-10-06 08:38:38RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
https://www.optimumcomms.com/wp-content/uploads/2026/10/rouge-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-06 08:38:382026-10-06 08:38:38RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-06 08:32:082026-10-06 08:32:08Poolbeg Pharma – Cancer Immunotherapy-Induced CRS Patent Granted in South Korea
https://www.optimumcomms.com/wp-content/uploads/2025/06/Rewind_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-06 08:00:422026-10-06 08:00:42Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
https://www.optimumcomms.com/wp-content/uploads/2024/11/Freya_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-05 14:37:452026-10-05 14:37:45Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-02 10:40:212026-10-02 10:40:21Hansa Biopharma to participate in 26th Annual Biotech in Europe Forum
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 12:55:062026-10-01 12:55:06ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 09:48:492026-10-01 09:48:49Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
https://www.optimumcomms.com/wp-content/uploads/2025/09/DaltonTx.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:32:122026-10-01 08:32:12DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
https://www.optimumcomms.com/wp-content/uploads/2026/09/numab-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:31:312026-10-01 08:31:31Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
https://www.optimumcomms.com/wp-content/uploads/2025/06/Atrogi_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:31:222026-10-01 08:31:22Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-30 12:01:062026-09-30 12:01:06R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-30 08:30:502026-09-30 08:30:50Oncoinvent to present three abstracts at EANM and ESMO 2026
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:48:462026-09-29 08:48:46Poolbeg Pharma plc – Interim Results for the six months to 30 June 2026
https://www.optimumcomms.com/wp-content/uploads/2026/09/Currus-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:39:512026-09-29 08:58:31Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
https://www.optimumcomms.com/wp-content/uploads/2025/06/Breye-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:34:152026-09-29 08:34:15Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
https://www.optimumcomms.com/wp-content/uploads/2026/06/Kither_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:30:132026-09-29 08:30:37Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPDWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
